If You'd Invested $5,000 In BioNTech's IPO, This Is How Much Money You'd Have Now

Coronavirus vaccine powerhouse BionNTech (NASDAQ: BNTX) made its U.S. public debut less than a year ago in October 2019, when it raised $150 million selling 10 million American depositary shares (ADSes) at $15 per ADS. Of course, it's unlikely that anyone investing last October could have anticipated BioNTech's rapid increase in valuation, which is mostly tied to the development of the drugmaker's coronavirus vaccine that recently entered phase 3 clinical development. BioNTech, like Moderna (NASDAQ: MRNA) that uses the same technology, was able to quickly design and develop its vaccine using the company's messenger RNA (mRNA) technology.